Sunday, October 22, 2017
Tailwinds' Take: new CEO Mark Day continues to build out a professional team as they look to take biOasis to the next level. We continue to believe that, for early stage biotech, this is the best risk/reward we have...
Vancouver, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) today announced the voting results from its Annual General Meeting held on Sept. 21, 2017 in Vancouver, British Columbia. The total number of shares represented in person or by proxy at the...
Tailwinds' Take: it looks like Dr. Day is being given the keys to the house as the founder steps aside. The new CEO's background and resume are impeccable and it's great to see someone of his experience take over...
This week, biOasis finally appears to be breaking out of its downtrend, which was started almost exactly a year ago. At that time the stock was much higher, however, it became apparent that the Company needed financing, which resulted...
Tailwinds' Take: this is an impressive group to be joining biOasis and certainly speaks to the opportunity facing biOasis. VANCOUVER, BC, Sept. 7, 2017, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;TSX.V:BTI), a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery...
Tailwinds' Take: I recently had the opportunity to spend an afternoon with Mark Day, the CEO of biOasis. When asked what my key takeaway from our time together was, I responded, "Mark is a dynamic visionary. He is the...
Tailwinds' Take: the licensing and partnering strategy at biOasis appeared to be on hold for a while as their new CEO settled into his role. This hire would seem to kick start this program. It remains to be seen...
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) welcomes Catherine London as executive vice president, head of corporate communications and investor relations, effective immediately. London will report to Dr. Mark Day, president and chief executive officer of biOasis. In this newly created...
On the back of his recent CEO update to shareholders, in which he expressed great enthusiasm for the Transcend Platform and the opportunity in front of biOasis, Mark Day, Phd, has just filed on a purchase of 33,000 shares...
Tailwinds' Take: this long awaited update from the new CEO shows that he's a thoughtful, reasoned leader who understands the technology and its place in the medical field. Going forward, biOasis will have a disciplined logical approach to studies...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address